Abstract
Acute myopathy is a common problem in intensive care units. Those at highest risk for developing critical illness myopathy are exposed to intravenous corticosteroids and paralytic agents during treatment of various illnesses. Diffuse weakness and failure to wean from mechanical ventilation are the most common clinical manifestations. Serum creatine kinase levels are variable. Electrodiagnostic studies reveal findings of a myopathic process, often with evidence of muscle membrane inexcitability. Based on animal model studies, the loss of muscle membrane excitability may be related to inactivation of sodium channels at the resting potential. In addition, human and animal pathologic studies reveal characteristic loss of myosin with relative preservation of other structural proteins. In some patients, there is also upregulation of proteolytic pathways, involving calpain and ubiquitin, in conjunction with increased apoptosis. Fortunately, the disorder is reversible, but there may be considerable morbidity.
Article PDF
Similar content being viewed by others
References and Recommended Reading
MacFarlane IA, Rosenthal FD: Severe myopathy after status asthamaticus. Lancet 1977, 2:615.
Douglass JA, Tuxen DV, Horne M, et al.: Myopathy in severe asthma. Am Rev Respir Dis 1992, 146:517–519.
Shee CD: Risk factors for hydrocortisone myopathy in acute severe asthma. Respir Med 1990, 84:229–233.
Williams TJ, O’Hehir RE, Czarny D, et al.: Acute myopathy in severe acute asthma treated with intravenously administered corticosteroids. Am Rev Respir Dis 1988, 137:460–463.
Leatherman JW, Fluegel WL, David WS, et al.: Muscle weakness in mechanically ventilated patients with severe asthma. Am J Respir Crit Care Med 1996, 153:1686–1690.
Lacomis D, Petrella JT, Giuliani MJ: Causes of neuromuscular weakness in the intensive care unit: a study of 92 patients. Muscle Nerve 1998, 21:610–617.
Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ: Acute myopathy of intensive care: clinical, EMG, and pathologic aspects. Ann Neurol 1996, 40:645–654.
Campellone JV, Lacomis D, Kramer DJ, et al.: Acute myopathy after liver transplantation. Neurology 1998, 50:46–53.
Miro Ò, Salemerón JM, Masanés F, et al.: Acute quadriplegic myopathy with myosin-deficient fibres after liver transplantation: defining the clinical picture and delimiting the risk factors. Transplantation 1999, 67:1144–1151.
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.Crit Care Med 1992, 20:867–874.
Showalter CJ, Engel AG: Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997, 20:316–322.
Deconinck N, Van Parijs V, Beckers-Bleukx G, Van den Bergh P: Critical illness myopathy unrelated to corticosteroids or neuromuscular blocking agents. Neuromuscul Disord 1998, 8:186–192.
Latronico N, Fenzi F, Recupero D, et al.: Critical illness myopathy and neuropathy. Lancet 1996, 347:1579–1582.
Zochodne DW, Bolton CF, Wells GA, et al.: Critical illness polyneuropathy: a complication of sepsis and multiple organ failure. Brain 1987, 110:819–842.
Campellone JV: Clinical approach to neuromuscular weakness in the critically ill patient. J Clin Neuromuscul Dis 2000, 1:151–158.
Segredo V, Caldwell JE, Matthay MA, et al.: Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992, 327:524–528.
Zochodne DW, Ramsay DA, Saly V, et al.: Acute necrotizing myopathy of intensive care: electrophysiological studies. Muscle Nerve 1994, 17:285–292.
Road J, Mackie G, Jiang T, et al.: Reversible paralysis with status asthmaticus, steroids, and pancuronium: clinical electrophysiological correlates. Muscle Nerve 1997, 20:1587–1590.
Hund E: Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001, 248:929–934.
Rich MM, Teener JW, Raps EC, et al.: Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 1996, 46:731–736.
Rich MM, Bird SJ, Raps EC, et al.: Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve 1997, 20:665–673.
Lacomis D, Bird S, Zochodne DZ: Critical illness myopathy [editorial]. Muscle Nerve 2000, 23:1785–1788.
Trojaborg W, Weimer LH, Hays AP: Electrophysiologic studies in critical illness associated weakness: myopathy or neuropathy- a reappraisal. Clin Neurophysiol 2001, 112:1586–1593. This report comprehensively assesses the electrodiagnostic feature of critical illness weakness, predominantly describing the features of critical illness myopathy.
Hund E, Genzwurker H, Bohrer H, et al.: Predominant involvement of motor fibres in patients with critical illness polyneuropathy. Br J Anaesth 1997, 78:274–278.
Matsumoto N, Nakamura T, Yasui Y, Torll J: Analysis of muscle proteins in acute quadriplegic myopathy. Muscle Nerve 2000, 23:1270–1276. Immunohistochemistry and stoichiometry were used to identify and quantitate myosin loss and maintenance of actin and regulatory proteins in four patients with critical illness myopathy.
Rouleau G, Karpati G, Carpenter S, et al.: Glucocorticoid excess induces preferential depletion of myosin in denervated skeletal muscle fibers. Muscle Nerve 1987, 10:428–438.
Massa R, Carpenter S, Holland P, Karpati G: Loss and renewal of thick myofilaments in glucocorticoid-treated rat soleus after denervation and reinnervation. Muscle Nerve 1992, 15:1290–1298.
Vedanarayanan VV, Vig PJS, Lawson N, et al.: Myopathy associated with heavy chain loss in rats with intramuscular botulinum toxin and high dose parenteral corticosteroids [abstract]. Neurology 1999, 52:A330.
Rich MM, Pinter MJ, Kraner SD, Barchi RL: Loss of electrical excitability in an animal model of acute quadriplegic myopathy. Ann Neurol 1997, 42:171–180.
Rich MM, Kraner SD, Barchi RL: Altered gene expression in steroid-treated denervated muscle. Neurobiol Dis 1999, 6:515–522.
Rich MM, Pinter MJ: Sodium channel inactivation in an animal model of acute quadriplegic myopathy. Ann Neurol 2001, 50:26–33. This paper is the most recent in a series of elegant experiments in the animal model of critical illness myopathy. Previous work is summarized, and inactivation of sodium channels in steroidtreated, denervated myofibers is found to be the cause of muscle membrane inexcitability.
Bazzi P, Moggio M, Prelle A, et al.: Inflammatory myopathy in intensive care patients [abstract]. J Neurol 1996,243:S111.
De Letter MA, van Doorn PA, Savelkoul HF, et al.: Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 2000, 106:206–213. An immunohistopathologic study from a mixed group of intensive care unit patients with acute myopathy and neuropathy. The authors suggest that activated leukocytes may have a role in causing weakness in these patients.
Salviati L, Laverda AM, Zancan L, et al.: Acute quadriplegic myopathy in a 17-month-old boy. J Child Neurol 2000, 15:63–66.
Di Giovanni S, Mirabella M, D’Amico A, et al.: Apoptotic features accompany acute quadriplegic myopathy. Neurology 2000, 55:854–858. The authors studied proteolytic pathways and apoptosis in three patients with critical illness myopathy. They suggest that these pathways may play a pathogenic role.
Guttridge DC, Mayo MW, Madrid LV, Baldwin AS Jr: NFkappaB- induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000, 289:2363–2366.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lacomis, D. Critical illness myopathy. Curr Rheumatol Rep 4, 403–408 (2002). https://doi.org/10.1007/s11926-002-0085-y
Issue Date:
DOI: https://doi.org/10.1007/s11926-002-0085-y